Synaptogen
Neurotrope Submits an Amended Protocol to the U.S. Food and Drug Administration for its Phase 2b Clinical Trial of its Lead Drug Candidate, Bryostatin-1, for the Treatment of Advanced …
Dec 5, 2014 · Apolipoprotein E (ApoE) is a critical signal for synaptogen-esis and synaptic maturation [101]. ApoE/cholesterol com-plex released from astrocytes is taken up through low …
is lower in apoE4 transgenic mice compared with apoE3 mice, indicating impaired synaptogen-esis (12, 13). ApoE4 is less efficient than apoE3 in transporting brain cholesterol (14) and is …
Traumatic brain injury (TBI) is a frequent consequence of vehicle, sport and war related injuries. More than 90% of TBI patients suffer mild injury (mTBI). However, the pathologies underlying …
Neurotrope Launches New Long-Term Clinical Trial of
NEW YORK, May 28, 2020 – Neurotrope, Inc. (Nasdaq: NTRP) today announced the launch of a new long-term study of Bryostatin-1 for the treatment of patients with Alzheimer’s disease …
Abhik Sen, Jarin Hongpaisan, Desheng Wang, Thomas J. Nelson and Daniel L. Alkon.
PKC Activation Prevents Synaptic Loss, A Elevation, and Cognitive Deficits in Alzheimer’s Disease Transgenic Mice Jarin Hongpaisan,1,2 Miao-Kun Sun,1 and Daniel L. Alkon1
Neurotrope Announces Publication Highlighting the Potential of ...
The complete publication in the Trends in Pharmacological Sciences: CellPress Reviews can be accessed here: https://www.synaptogen.com/wp-content/uploads/2019//08/TiPS2019.pdf and …
Synaptogenix | Neurotrope, In Consultation With Leading …
The Company has selected Worldwide Clinical Trials (Worldwide) to conduct this confirmatory Phase 2 clinical trial. Worldwide is a leading global clinical research organization and the …
Neurotrope BioScience to Present at the Oppenheimer 27th …
NEW YORK, March 16, 2017 PRNewswire/ — Neurotrope, Inc. (OTCQB: NTRP), a clinical-stage biopharmaceutical company developing novel therapeutics for neurodegenerative diseases, …